People with type 2 diabetes who start insulin and take statins are significantly less likely to die from any cause over the next five years than those who don’t take statins.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of RCTs could determine whether statin initiation after insulin start consistently reduces all-cause mortality across diverse populations, quantifying the effect size by statin type and baseline risk.
A systematic review and meta-analysis of all randomized trials comparing statin initiation versus placebo in adults with type 2 diabetes newly starting insulin, with all-cause mortality as primary endpoint, stratified by statin type, dose, and baseline HbA1c, including trials with ≥500 participants and ≥5-year follow-up.
An RCT could determine whether statin initiation directly reduces all-cause mortality in insulin-initiating patients, independent of selection bias.
A double-blind, placebo-controlled RCT of 4000 adults with type 2 diabetes (HbA1c ≥8.0%) newly starting insulin, randomized to rosuvastatin 10mg/day or placebo, with all-cause mortality as primary endpoint over 5 years, and secondary endpoints of MACE, HbA1c, and safety.
A prospective cohort could confirm whether statin use correlates with lower all-cause mortality after insulin initiation after adjusting for comorbidities and lifestyle factors.
A prospective cohort of 6000 adults with type 2 diabetes initiating insulin, with annual mortality tracking, statin use, HbA1c, LDL-C, renal function, and smoking status measured for 5 years, adjusting for baseline and time-varying covariates.
A case-control study could test whether individuals who died within 5 years of insulin initiation were less likely to have used statins compared to survivors.
A case-control study comparing 1000 adults with type 2 diabetes who died within 5 years of insulin initiation (cases) to 1000 matched survivors, assessing prior statin use, type, duration, and dose before insulin start.
A cross-sectional analysis could show whether statin use correlates with lower mortality prevalence at a single time point after insulin initiation, but cannot assess incidence or causality.
A cross-sectional analysis of 10,000 adults with type 2 diabetes who started insulin 1–5 years prior, comparing mortality prevalence between statin users and non-users, adjusting for age and baseline HbA1c.